Stroke - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：326頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Stroke - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Stroke - Pipeline Review, H1 2014’, provides an overview of the Stroke’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Stroke and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Stroke
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Stroke and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Stroke pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Stroke
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Stroke pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Stroke - Pipeline Review, H1 2014’, provides an overview of the Stroke’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Stroke and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Stroke
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Stroke and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Stroke pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Stroke
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Stroke pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Stroke Overview 11
Therapeutics Development 12
Pipeline Products for Stroke - Overview 12
Pipeline Products for Stroke - Comparative Analysis 13
Stroke - Therapeutics under Development by Companies 14
Stroke - Therapeutics under Investigation by Universities/Institutes 20
Stroke - Pipeline Products Glance 23
Late Stage Products 23
Clinical Stage Products 24
Early Stage Products 25
Unknown Stage Products 26
Stroke - Products under Development by Companies 27
Stroke - Products under Investigation by Universities/Institutes 33
Stroke - Companies Involved in Therapeutics Development 35
F. Hoffmann-La Roche Ltd. 35
AstraZeneca PLC 36
GlaxoSmithKline plc 37
CardioVascular BioTherapeutics, Inc. 38
Acorda Therapeutics, Inc. 39
Glenmark Pharmaceuticals Ltd. 40
Jeil Pharmaceutical Co., Ltd. 41
Novavax, Inc. 42
Pfizer Inc. 43
Venus Remedies Limited 44
Anavex Life Sciences Corp. 45
Neuralstem, Inc. 46
Living Cell Technologies Limited 47
Mesoblast Limited 48
Neuren Pharmaceuticals Limited 49
Mast Therapeutics, Inc. 50
Kolon Life Science, Inc. 51
WhanIn Pharmaceutical Co., Ltd. 52
RegeneRx Biopharmaceuticals, Inc. 53
Pozen, Inc. 54
Dongwha Pharm Co., Ltd. 55
Green Cross Corporation 56
PhytoHealth Corporation 57
Phylogica Limited 58
Huons Co., Ltd. 59
NeuroVive Pharmaceutical AB 60
D-Pharm Ltd. 61
StemCells, Inc. 62
Scynexis, Inc. 63
SynZyme Technologies, LLC 64
AGY Therapeutics, Inc. 65
Phoenix Biotechnology, Inc. 66
Regado Biosciences, Inc. 67
Fina Biotech 68
Angion Biomedica Corp. 69
GliaMed, Inc. 70
SanBio, Inc. 71
Diakron Pharmaceuticals, Inc. 72
Lacer, S.A. 73
ReCyte Therapeutics, Inc. 74
MAPREG 75
Medestea Research & Production S.p.A. 76
Encore Therapeutics Inc. 77
CoDa Therapeutics, Inc. 78
Georgia Tech Research Corporation 79
ArmaGen Technologies, Inc. 80
Sinapis Pharma, Inc 81
CHA Bio & Diostech Co., Ltd. 82
Vicore Pharma AB 83
InVasc Therapeutics, Inc. 84
Pharmicell Co., Ltd. 85
Tarix Pharmaceuticals LTD. 86
Targazyme, Inc. 87
Ampio Pharmaceuticals, Inc. 88
APT Therapeutics, Inc. 89
Stealth Peptides Inc. 90
Mnemosyne Pharmaceuticals, Inc. 91
Inbiopro Solutions Pvt. Ltd. 92
Aronora, LLC 93
Neurotec Pharma SL 94
Generon (Shanghai) Corporation Ltd. 95
Covigilance sro 96
Stroke - Therapeutics Assessment 97
Assessment by Monotherapy Products 97
Assessment by Combination Products 98
Assessment by Target 99
Assessment by Mechanism of Action 105
Assessment by Route of Administration 111
Assessment by Molecule Type 114
Drug Profiles 117
(aspirin EC + omeprazole IR) - Drug Profile 117
(enteric coated aspirin + immediate release omeprazole) - Drug Profile 118
ticagrelor - Drug Profile 120
Cerecellgram-Stroke - Drug Profile 123
lithium carbonate - Drug Profile 124
Erythropoietin - Drug Profile 125
GSK-249320 - Drug Profile 126
LA-419 - Drug Profile 128
dalfampridine ER - Drug Profile 129
PF-03049423 - Drug Profile 131
R-15 - Drug Profile 132
TRX-1 - Drug Profile 134
HU-010 - Drug Profile 135
donepezil hydrochloride - Drug Profile 136
DP-4088 - Drug Profile 137
metamfetamine - Drug Profile 139
GCC-2107 - Drug Profile 140
JPI-289 - Drug Profile 141
PHN-015 - Drug Profile 142
F-637 - Drug Profile 143
GM-1485 - Drug Profile 144
ANAVEX-2-73 - Drug Profile 146
ANAVEX-1-41 - Drug Profile 148
DP-460 - Drug Profile 149
OPC-1 - Drug Profile 150
CVBT-141F - Drug Profile 152
RGN-352 - Drug Profile 153
ANAVEX-19-144 - Drug Profile 155
cimaglermin alfa - Drug Profile 157
AGT-190 - Drug Profile 159
NNZ-2591 - Drug Profile 160
PBI-05204 - Drug Profile 161
Human Neural Stem Cells - Drug Profile 163
MTP-131 - Drug Profile 165
AGT-115 - Drug Profile 167
GBR-600 - Drug Profile 168
NSI-189 - Drug Profile 169
INV-155 - Drug Profile 171
CIGB-845 - Drug Profile 172
AB-002 - Drug Profile 173
Vascular Program - Drug Profile 174
NTCELL - Drug Profile 175
PanCyte - Drug Profile 177
Stem Cell Therapy For Brain Stroke - Drug Profile 179
DMI-4983 - Drug Profile 180
LA-8045 - Drug Profile 181
C-21 - Drug Profile 182
poloxamer - Drug Profile 184
HYNR-CS - Drug Profile 185
ND-478 - Drug Profile 186
KLS-Nst - Drug Profile 187
WIB-801C - Drug Profile 188
COR-3 - Drug Profile 189
COR-2 - Drug Profile 190
NT-KC-005 - Drug Profile 191
APT-102 - Drug Profile 192
E-Selectin Tolerogen - Drug Profile 193
AGY-208 Agonist for Ischemic Stroke - Drug Profile 194
Stroke Program - Drug Profile 195
EPO-Variant - Drug Profile 196
miR-29b - Drug Profile 197
P2Y Purinergic Receptor Agonist - Drug Profile 198
Dihydroxyflavone - Drug Profile 199
GSK-3 Inhibitors for CNS and Metabolic disorders - Drug Profile 201
Peptides to Inhibit MHC Class I and II for CNS Disorders - Drug Profile 202
IAC VITA - Drug Profile 203
COVEDS-34 - Drug Profile 205
NBI-18 - Drug Profile 206
VitalHeme - Drug Profile 207
Neural Regeneration Peptides For Stroke - Drug Profile 208
ASC-102 - Drug Profile 209
NPC Program - Drug Profile 210
Human Induced Pluripotent Stem Cells - Drug Profile 211
Aza-Peptide Epoxides - Drug Profile 212
Glucagon Like Peptide-1 - Drug Profile 213
Glucagon Like Peptide-1 Analogues - Drug Profile 215
Drug For Stroke - Drug Profile 216
Small Hairpin RNA Inhibitory Molecule - Drug Profile 217
Allogenic Mesenchymal Precursor Cells For Parkinson Disease and Stroke - Drug Profile 218
Fisetin - Drug Profile 219
Peptagon - Drug Profile 220
Small Molecule to Activate Voltage-Gated Sodium Channe for Central Nervous System Disorders - Drug Profile 221
Small Molecule to Inhibit TGF-Beta for Stroke and Neurodegenerative Diseases - Drug Profile 222
PYC-35 - Drug Profile 223
PYC-36 - Drug Profile 224
PYC-38 - Drug Profile 225
PYC-98 - Drug Profile 226
UPEI-100 - Drug Profile 227
Stem Cell Therapy for Cerebral Stroke - Drug Profile 228
Anti Platelet Program - Drug Profile 229
NeuroSTAT - Drug Profile 230
Drug For Stroke - Drug Profile 231
ANG-3186 - Drug Profile 232
Cyclophilin Inhibitory Compounds - Drug Profile 233
Nonimmunosuppressive Cyclosporin Analog Molecule Program - Drug Profile 234
Mutated Tissue Plasminogen Activator - Drug Profile 236
Lipophilic Phenolic Antioxidants - Drug Profile 237
NMDA Receptor Antagonists for Neurodegenerative Disorders - Drug Profile 238
Small Molecules for Thrombosis and Stroke - Drug Profile 239
Tumor Necrosis Factors-Alpha Antagonist - Drug Profile 240
C3aR Agonist Peptides - Drug Profile 241
MAP-46 - Drug Profile 242
RGN-352 - Drug Profile 243
VACNO - Drug Profile 245
SB-623 - Drug Profile 246
progesterone - Drug Profile 247
IBPB-005-ET - Drug Profile 248
NHP-554C - Drug Profile 249
NHP-554CZ - Drug Profile 250
NR-2A Modulators - Drug Profile 251
XEN-103 - Drug Profile 252
VRP-1009 - Drug Profile 253
NFx-101 - Drug Profile 254
Stroke - Recent Pipeline Updates 255
Stroke - Dormant Projects 299
Stroke - Discontinued Products 305
Stroke - Product Development Milestones 307
Featured News & Press Releases 307
Appendix 317
Methodology 317
Coverage 317
Secondary Research 317
Primary Research 317
Expert Panel Validation 317
Contact Us 318
Disclaimer 318
List of Tables
Number of Products under Development for Stroke, H1 2014 20
Number of Products under Development for Stroke - Comparative Analysis, H1 2014 21
Number of Products under Development by Companies, H1 2014 23
Number of Products under Development by Companies, H1 2014 (Contd..1) 24
Number of Products under Development by Companies, H1 2014 (Contd..2) 25
Number of Products under Development by Companies, H1 2014 (Contd..3) 26
Number of Products under Development by Companies, H1 2014 (Contd..4) 27
Number of Products under Investigation by Universities/Institutes, H1 2014 29
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 30
Comparative Analysis by Late Stage Development, H1 2014 31
Comparative Analysis by Clinical Stage Development, H1 2014 32
Comparative Analysis by Early Stage Development, H1 2014 33
Comparative Analysis by Unknown Stage Development, H1 2014 34
Products under Development by Companies, H1 2014 35
Products under Development by Companies, H1 2014 (Contd..1) 36
Products under Development by Companies, H1 2014 (Contd..2) 37
Products under Development by Companies, H1 2014 (Contd..3) 38
Products under Development by Companies, H1 2014 (Contd..4) 39
Products under Development by Companies, H1 2014 (Contd..5) 40
Products under Investigation by Universities/Institutes, H1 2014 41
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 42
Stroke - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 43
Stroke - Pipeline by AstraZeneca PLC, H1 2014 44
Stroke - Pipeline by GlaxoSmithKline plc, H1 2014 45
Stroke - Pipeline by CardioVascular BioTherapeutics, Inc., H1 2014 46
Stroke - Pipeline by Acorda Therapeutics, Inc., H1 2014 47
Stroke - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2014 48
Stroke - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2014 49
Stroke - Pipeline by Novavax, Inc., H1 2014 50
Stroke - Pipeline by Pfizer Inc., H1 2014 51
Stroke - Pipeline by Venus Remedies Limited, H1 2014 52
Stroke - Pipeline by Anavex Life Sciences Corp., H1 2014 53
Stroke - Pipeline by Neuralstem, Inc., H1 2014 54
Stroke - Pipeline by Living Cell Technologies Limited, H1 2014 55
Stroke - Pipeline by Mesoblast Limited, H1 2014 56
Stroke - Pipeline by Neuren Pharmaceuticals Limited, H1 2014 57
Stroke - Pipeline by Mast Therapeutics, Inc., H1 2014 58
Stroke - Pipeline by Kolon Life Science, Inc., H1 2014 59
Stroke - Pipeline by WhanIn Pharmaceutical Co., Ltd., H1 2014 60
Stroke - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2014 61
Stroke - Pipeline by Pozen, Inc., H1 2014 62
Stroke - Pipeline by Dongwha Pharm Co., Ltd., H1 2014 63
Stroke - Pipeline by Green Cross Corporation, H1 2014 64
Stroke - Pipeline by PhytoHealth Corporation, H1 2014 65
Stroke - Pipeline by Phylogica Limited, H1 2014 66
Stroke - Pipeline by Huons Co., Ltd., H1 2014 67
Stroke - Pipeline by NeuroVive Pharmaceutical AB, H1 2014 68
Stroke - Pipeline by D-Pharm Ltd., H1 2014 69
Stroke - Pipeline by StemCells, Inc., H1 2014 70
Stroke - Pipeline by Scynexis, Inc., H1 2014 71
Stroke - Pipeline by SynZyme Technologies, LLC, H1 2014 72
Stroke - Pipeline by AGY Therapeutics, Inc., H1 2014 73
Stroke - Pipeline by Phoenix Biotechnology, Inc., H1 2014 74
Stroke - Pipeline by Regado Biosciences, Inc., H1 2014 75
Stroke - Pipeline by Fina Biotech, H1 2014 76
Stroke - Pipeline by Angion Biomedica Corp., H1 2014 77
Stroke - Pipeline by GliaMed, Inc., H1 2014 78
Stroke - Pipeline by SanBio, Inc., H1 2014 79
Stroke - Pipeline by Diakron Pharmaceuticals, Inc., H1 2014 80
Stroke - Pipeline by Lacer, S.A., H1 2014 81
Stroke - Pipeline by ReCyte Therapeutics, Inc., H1 2014 82
Stroke - Pipeline by MAPREG, H1 2014 83
Stroke - Pipeline by Medestea Research & Production S.p.A., H1 2014 84
Stroke - Pipeline by Encore Therapeutics Inc., H1 2014 85
Stroke - Pipeline by CoDa Therapeutics, Inc., H1 2014 86
Stroke - Pipeline by Georgia Tech Research Corporation, H1 2014 87
Stroke - Pipeline by ArmaGen Technologies, Inc., H1 2014 88
Stroke - Pipeline by Sinapis Pharma, Inc, H1 2014 89
Stroke - Pipeline by CHA Bio & Diostech Co., Ltd., H1 2014 90
Stroke - Pipeline by Vicore Pharma AB, H1 2014 91
Stroke - Pipeline by InVasc Therapeutics, Inc., H1 2014 92
Stroke - Pipeline by Pharmicell Co., Ltd., H1 2014 93
Stroke - Pipeline by Tarix Pharmaceuticals LTD., H1 2014 94
Stroke - Pipeline by Targazyme, Inc., H1 2014 95
Stroke - Pipeline by Ampio Pharmaceuticals, Inc., H1 2014 96
Stroke - Pipeline by APT Therapeutics, Inc., H1 2014 97
Stroke - Pipeline by Stealth Peptides Inc., H1 2014 98
Stroke - Pipeline by Mnemosyne Pharmaceuticals, Inc., H1 2014 99
Stroke - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2014 100
Stroke - Pipeline by Aronora, LLC, H1 2014 101
Stroke - Pipeline by Neurotec Pharma SL, H1 2014 102
Stroke - Pipeline by Generon (Shanghai) Corporation Ltd., H1 2014 103
Stroke - Pipeline by Covigilance sro, H1 2014 104
Assessment by Monotherapy Products, H1 2014 105
Assessment by Combination Products, H1 2014 106
Number of Products by Stage and Target, H1 2014 109
Number of Products by Stage and Mechanism of Action, H1 2014 115
Number of Products by Stage and Route of Administration, H1 2014 121
Number of Products by Stage and Molecule Type, H1 2014 124
Stroke Therapeutics - Recent Pipeline Updates, H1 2014 263
Stroke - Dormant Projects, H1 2014 307
Stroke - Dormant Projects (Contd..1), H1 2014 308
Stroke - Dormant Projects (Contd..2), H1 2014 309
Stroke - Dormant Projects (Contd..3), H1 2014 310
Stroke - Dormant Projects (Contd..4), H1 2014 311
Stroke - Dormant Projects (Contd..5), H1 2014 312
Stroke - Discontinued Products, H1 2014 313
Stroke - Discontinued Products (Contd..1), H1 2014 314
List of Figures
Number of Products under Development for Stroke, H1 2014 20
Number of Products under Development for Stroke - Comparative Analysis, H1 2014 21
Number of Products under Development by Companies, H1 2014 22
Number of Products under Investigation by Universities/Institutes, H1 2014 28
Comparative Analysis by Late Stage Development, H1 2014 31
Comparative Analysis by Clinical Stage Development, H1 2014 32
Comparative Analysis by Early Stage Products, H1 2014 33
Assessment by Monotherapy Products, H1 2014 105
Number of Products by Top 10 Target, H1 2014 107
Number of Products by Stage and Top 10 Target, H1 2014 108
Number of Products by Top 10 Mechanism of Action, H1 2014 113
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 114
Number of Products by Top 10 Route of Administration, H1 2014 119
Number of Products by Stage and Top 10 Route of Administration, H1 2014 120
Number of Products by Top 10 Molecule Type, H1 2014 122
Number of Products by Stage and Top 10 Molecule Type, H1 2014 123
Table of Contents 2
List of Tables 6
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Stroke Overview 11
Therapeutics Development 12
Pipeline Products for Stroke - Overview 12
Pipeline Products for Stroke - Comparative Analysis 13
Stroke - Therapeutics under Development by Companies 14
Stroke - Therapeutics under Investigation by Universities/Institutes 20
Stroke - Pipeline Products Glance 23
Late Stage Products 23
Clinical Stage Products 24
Early Stage Products 25
Unknown Stage Products 26
Stroke - Products under Development by Companies 27
Stroke - Products under Investigation by Universities/Institutes 33
Stroke - Companies Involved in Therapeutics Development 35
F. Hoffmann-La Roche Ltd. 35
AstraZeneca PLC 36
GlaxoSmithKline plc 37
CardioVascular BioTherapeutics, Inc. 38
Acorda Therapeutics, Inc. 39
Glenmark Pharmaceuticals Ltd. 40
Jeil Pharmaceutical Co., Ltd. 41
Novavax, Inc. 42
Pfizer Inc. 43
Venus Remedies Limited 44
Anavex Life Sciences Corp. 45
Neuralstem, Inc. 46
Living Cell Technologies Limited 47
Mesoblast Limited 48
Neuren Pharmaceuticals Limited 49
Mast Therapeutics, Inc. 50
Kolon Life Science, Inc. 51
WhanIn Pharmaceutical Co., Ltd. 52
RegeneRx Biopharmaceuticals, Inc. 53
Pozen, Inc. 54
Dongwha Pharm Co., Ltd. 55
Green Cross Corporation 56
PhytoHealth Corporation 57
Phylogica Limited 58
Huons Co., Ltd. 59
NeuroVive Pharmaceutical AB 60
D-Pharm Ltd. 61
StemCells, Inc. 62
Scynexis, Inc. 63
SynZyme Technologies, LLC 64
AGY Therapeutics, Inc. 65
Phoenix Biotechnology, Inc. 66
Regado Biosciences, Inc. 67
Fina Biotech 68
Angion Biomedica Corp. 69
GliaMed, Inc. 70
SanBio, Inc. 71
Diakron Pharmaceuticals, Inc. 72
Lacer, S.A. 73
ReCyte Therapeutics, Inc. 74
MAPREG 75
Medestea Research & Production S.p.A. 76
Encore Therapeutics Inc. 77
CoDa Therapeutics, Inc. 78
Georgia Tech Research Corporation 79
ArmaGen Technologies, Inc. 80
Sinapis Pharma, Inc 81
CHA Bio & Diostech Co., Ltd. 82
Vicore Pharma AB 83
InVasc Therapeutics, Inc. 84
Pharmicell Co., Ltd. 85
Tarix Pharmaceuticals LTD. 86
Targazyme, Inc. 87
Ampio Pharmaceuticals, Inc. 88
APT Therapeutics, Inc. 89
Stealth Peptides Inc. 90
Mnemosyne Pharmaceuticals, Inc. 91
Inbiopro Solutions Pvt. Ltd. 92
Aronora, LLC 93
Neurotec Pharma SL 94
Generon (Shanghai) Corporation Ltd. 95
Covigilance sro 96
Stroke - Therapeutics Assessment 97
Assessment by Monotherapy Products 97
Assessment by Combination Products 98
Assessment by Target 99
Assessment by Mechanism of Action 105
Assessment by Route of Administration 111
Assessment by Molecule Type 114
Drug Profiles 117
(aspirin EC + omeprazole IR) - Drug Profile 117
(enteric coated aspirin + immediate release omeprazole) - Drug Profile 118
ticagrelor - Drug Profile 120
Cerecellgram-Stroke - Drug Profile 123
lithium carbonate - Drug Profile 124
Erythropoietin - Drug Profile 125
GSK-249320 - Drug Profile 126
LA-419 - Drug Profile 128
dalfampridine ER - Drug Profile 129
PF-03049423 - Drug Profile 131
R-15 - Drug Profile 132
TRX-1 - Drug Profile 134
HU-010 - Drug Profile 135
donepezil hydrochloride - Drug Profile 136
DP-4088 - Drug Profile 137
metamfetamine - Drug Profile 139
GCC-2107 - Drug Profile 140
JPI-289 - Drug Profile 141
PHN-015 - Drug Profile 142
F-637 - Drug Profile 143
GM-1485 - Drug Profile 144
ANAVEX-2-73 - Drug Profile 146
ANAVEX-1-41 - Drug Profile 148
DP-460 - Drug Profile 149
OPC-1 - Drug Profile 150
CVBT-141F - Drug Profile 152
RGN-352 - Drug Profile 153
ANAVEX-19-144 - Drug Profile 155
cimaglermin alfa - Drug Profile 157
AGT-190 - Drug Profile 159
NNZ-2591 - Drug Profile 160
PBI-05204 - Drug Profile 161
Human Neural Stem Cells - Drug Profile 163
MTP-131 - Drug Profile 165
AGT-115 - Drug Profile 167
GBR-600 - Drug Profile 168
NSI-189 - Drug Profile 169
INV-155 - Drug Profile 171
CIGB-845 - Drug Profile 172
AB-002 - Drug Profile 173
Vascular Program - Drug Profile 174
NTCELL - Drug Profile 175
PanCyte - Drug Profile 177
Stem Cell Therapy For Brain Stroke - Drug Profile 179
DMI-4983 - Drug Profile 180
LA-8045 - Drug Profile 181
C-21 - Drug Profile 182
poloxamer - Drug Profile 184
HYNR-CS - Drug Profile 185
ND-478 - Drug Profile 186
KLS-Nst - Drug Profile 187
WIB-801C - Drug Profile 188
COR-3 - Drug Profile 189
COR-2 - Drug Profile 190
NT-KC-005 - Drug Profile 191
APT-102 - Drug Profile 192
E-Selectin Tolerogen - Drug Profile 193
AGY-208 Agonist for Ischemic Stroke - Drug Profile 194
Stroke Program - Drug Profile 195
EPO-Variant - Drug Profile 196
miR-29b - Drug Profile 197
P2Y Purinergic Receptor Agonist - Drug Profile 198
Dihydroxyflavone - Drug Profile 199
GSK-3 Inhibitors for CNS and Metabolic disorders - Drug Profile 201
Peptides to Inhibit MHC Class I and II for CNS Disorders - Drug Profile 202
IAC VITA - Drug Profile 203
COVEDS-34 - Drug Profile 205
NBI-18 - Drug Profile 206
VitalHeme - Drug Profile 207
Neural Regeneration Peptides For Stroke - Drug Profile 208
ASC-102 - Drug Profile 209
NPC Program - Drug Profile 210
Human Induced Pluripotent Stem Cells - Drug Profile 211
Aza-Peptide Epoxides - Drug Profile 212
Glucagon Like Peptide-1 - Drug Profile 213
Glucagon Like Peptide-1 Analogues - Drug Profile 215
Drug For Stroke - Drug Profile 216
Small Hairpin RNA Inhibitory Molecule - Drug Profile 217
Allogenic Mesenchymal Precursor Cells For Parkinson Disease and Stroke - Drug Profile 218
Fisetin - Drug Profile 219
Peptagon - Drug Profile 220
Small Molecule to Activate Voltage-Gated Sodium Channe for Central Nervous System Disorders - Drug Profile 221
Small Molecule to Inhibit TGF-Beta for Stroke and Neurodegenerative Diseases - Drug Profile 222
PYC-35 - Drug Profile 223
PYC-36 - Drug Profile 224
PYC-38 - Drug Profile 225
PYC-98 - Drug Profile 226
UPEI-100 - Drug Profile 227
Stem Cell Therapy for Cerebral Stroke - Drug Profile 228
Anti Platelet Program - Drug Profile 229
NeuroSTAT - Drug Profile 230
Drug For Stroke - Drug Profile 231
ANG-3186 - Drug Profile 232
Cyclophilin Inhibitory Compounds - Drug Profile 233
Nonimmunosuppressive Cyclosporin Analog Molecule Program - Drug Profile 234
Mutated Tissue Plasminogen Activator - Drug Profile 236
Lipophilic Phenolic Antioxidants - Drug Profile 237
NMDA Receptor Antagonists for Neurodegenerative Disorders - Drug Profile 238
Small Molecules for Thrombosis and Stroke - Drug Profile 239
Tumor Necrosis Factors-Alpha Antagonist - Drug Profile 240
C3aR Agonist Peptides - Drug Profile 241
MAP-46 - Drug Profile 242
RGN-352 - Drug Profile 243
VACNO - Drug Profile 245
SB-623 - Drug Profile 246
progesterone - Drug Profile 247
IBPB-005-ET - Drug Profile 248
NHP-554C - Drug Profile 249
NHP-554CZ - Drug Profile 250
NR-2A Modulators - Drug Profile 251
XEN-103 - Drug Profile 252
VRP-1009 - Drug Profile 253
NFx-101 - Drug Profile 254
Stroke - Recent Pipeline Updates 255
Stroke - Dormant Projects 299
Stroke - Discontinued Products 305
Stroke - Product Development Milestones 307
Featured News & Press Releases 307
Appendix 317
Methodology 317
Coverage 317
Secondary Research 317
Primary Research 317
Expert Panel Validation 317
Contact Us 318
Disclaimer 318
List of Tables
Number of Products under Development for Stroke, H1 2014 20
Number of Products under Development for Stroke - Comparative Analysis, H1 2014 21
Number of Products under Development by Companies, H1 2014 23
Number of Products under Development by Companies, H1 2014 (Contd..1) 24
Number of Products under Development by Companies, H1 2014 (Contd..2) 25
Number of Products under Development by Companies, H1 2014 (Contd..3) 26
Number of Products under Development by Companies, H1 2014 (Contd..4) 27
Number of Products under Investigation by Universities/Institutes, H1 2014 29
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 30
Comparative Analysis by Late Stage Development, H1 2014 31
Comparative Analysis by Clinical Stage Development, H1 2014 32
Comparative Analysis by Early Stage Development, H1 2014 33
Comparative Analysis by Unknown Stage Development, H1 2014 34
Products under Development by Companies, H1 2014 35
Products under Development by Companies, H1 2014 (Contd..1) 36
Products under Development by Companies, H1 2014 (Contd..2) 37
Products under Development by Companies, H1 2014 (Contd..3) 38
Products under Development by Companies, H1 2014 (Contd..4) 39
Products under Development by Companies, H1 2014 (Contd..5) 40
Products under Investigation by Universities/Institutes, H1 2014 41
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 42
Stroke - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 43
Stroke - Pipeline by AstraZeneca PLC, H1 2014 44
Stroke - Pipeline by GlaxoSmithKline plc, H1 2014 45
Stroke - Pipeline by CardioVascular BioTherapeutics, Inc., H1 2014 46
Stroke - Pipeline by Acorda Therapeutics, Inc., H1 2014 47
Stroke - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2014 48
Stroke - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2014 49
Stroke - Pipeline by Novavax, Inc., H1 2014 50
Stroke - Pipeline by Pfizer Inc., H1 2014 51
Stroke - Pipeline by Venus Remedies Limited, H1 2014 52
Stroke - Pipeline by Anavex Life Sciences Corp., H1 2014 53
Stroke - Pipeline by Neuralstem, Inc., H1 2014 54
Stroke - Pipeline by Living Cell Technologies Limited, H1 2014 55
Stroke - Pipeline by Mesoblast Limited, H1 2014 56
Stroke - Pipeline by Neuren Pharmaceuticals Limited, H1 2014 57
Stroke - Pipeline by Mast Therapeutics, Inc., H1 2014 58
Stroke - Pipeline by Kolon Life Science, Inc., H1 2014 59
Stroke - Pipeline by WhanIn Pharmaceutical Co., Ltd., H1 2014 60
Stroke - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2014 61
Stroke - Pipeline by Pozen, Inc., H1 2014 62
Stroke - Pipeline by Dongwha Pharm Co., Ltd., H1 2014 63
Stroke - Pipeline by Green Cross Corporation, H1 2014 64
Stroke - Pipeline by PhytoHealth Corporation, H1 2014 65
Stroke - Pipeline by Phylogica Limited, H1 2014 66
Stroke - Pipeline by Huons Co., Ltd., H1 2014 67
Stroke - Pipeline by NeuroVive Pharmaceutical AB, H1 2014 68
Stroke - Pipeline by D-Pharm Ltd., H1 2014 69
Stroke - Pipeline by StemCells, Inc., H1 2014 70
Stroke - Pipeline by Scynexis, Inc., H1 2014 71
Stroke - Pipeline by SynZyme Technologies, LLC, H1 2014 72
Stroke - Pipeline by AGY Therapeutics, Inc., H1 2014 73
Stroke - Pipeline by Phoenix Biotechnology, Inc., H1 2014 74
Stroke - Pipeline by Regado Biosciences, Inc., H1 2014 75
Stroke - Pipeline by Fina Biotech, H1 2014 76
Stroke - Pipeline by Angion Biomedica Corp., H1 2014 77
Stroke - Pipeline by GliaMed, Inc., H1 2014 78
Stroke - Pipeline by SanBio, Inc., H1 2014 79
Stroke - Pipeline by Diakron Pharmaceuticals, Inc., H1 2014 80
Stroke - Pipeline by Lacer, S.A., H1 2014 81
Stroke - Pipeline by ReCyte Therapeutics, Inc., H1 2014 82
Stroke - Pipeline by MAPREG, H1 2014 83
Stroke - Pipeline by Medestea Research & Production S.p.A., H1 2014 84
Stroke - Pipeline by Encore Therapeutics Inc., H1 2014 85
Stroke - Pipeline by CoDa Therapeutics, Inc., H1 2014 86
Stroke - Pipeline by Georgia Tech Research Corporation, H1 2014 87
Stroke - Pipeline by ArmaGen Technologies, Inc., H1 2014 88
Stroke - Pipeline by Sinapis Pharma, Inc, H1 2014 89
Stroke - Pipeline by CHA Bio & Diostech Co., Ltd., H1 2014 90
Stroke - Pipeline by Vicore Pharma AB, H1 2014 91
Stroke - Pipeline by InVasc Therapeutics, Inc., H1 2014 92
Stroke - Pipeline by Pharmicell Co., Ltd., H1 2014 93
Stroke - Pipeline by Tarix Pharmaceuticals LTD., H1 2014 94
Stroke - Pipeline by Targazyme, Inc., H1 2014 95
Stroke - Pipeline by Ampio Pharmaceuticals, Inc., H1 2014 96
Stroke - Pipeline by APT Therapeutics, Inc., H1 2014 97
Stroke - Pipeline by Stealth Peptides Inc., H1 2014 98
Stroke - Pipeline by Mnemosyne Pharmaceuticals, Inc., H1 2014 99
Stroke - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2014 100
Stroke - Pipeline by Aronora, LLC, H1 2014 101
Stroke - Pipeline by Neurotec Pharma SL, H1 2014 102
Stroke - Pipeline by Generon (Shanghai) Corporation Ltd., H1 2014 103
Stroke - Pipeline by Covigilance sro, H1 2014 104
Assessment by Monotherapy Products, H1 2014 105
Assessment by Combination Products, H1 2014 106
Number of Products by Stage and Target, H1 2014 109
Number of Products by Stage and Mechanism of Action, H1 2014 115
Number of Products by Stage and Route of Administration, H1 2014 121
Number of Products by Stage and Molecule Type, H1 2014 124
Stroke Therapeutics - Recent Pipeline Updates, H1 2014 263
Stroke - Dormant Projects, H1 2014 307
Stroke - Dormant Projects (Contd..1), H1 2014 308
Stroke - Dormant Projects (Contd..2), H1 2014 309
Stroke - Dormant Projects (Contd..3), H1 2014 310
Stroke - Dormant Projects (Contd..4), H1 2014 311
Stroke - Dormant Projects (Contd..5), H1 2014 312
Stroke - Discontinued Products, H1 2014 313
Stroke - Discontinued Products (Contd..1), H1 2014 314
List of Figures
Number of Products under Development for Stroke, H1 2014 20
Number of Products under Development for Stroke - Comparative Analysis, H1 2014 21
Number of Products under Development by Companies, H1 2014 22
Number of Products under Investigation by Universities/Institutes, H1 2014 28
Comparative Analysis by Late Stage Development, H1 2014 31
Comparative Analysis by Clinical Stage Development, H1 2014 32
Comparative Analysis by Early Stage Products, H1 2014 33
Assessment by Monotherapy Products, H1 2014 105
Number of Products by Top 10 Target, H1 2014 107
Number of Products by Stage and Top 10 Target, H1 2014 108
Number of Products by Top 10 Mechanism of Action, H1 2014 113
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 114
Number of Products by Top 10 Route of Administration, H1 2014 119
Number of Products by Stage and Top 10 Route of Administration, H1 2014 120
Number of Products by Top 10 Molecule Type, H1 2014 122
Number of Products by Stage and Top 10 Molecule Type, H1 2014 123
